Clinical usefulness of [(18)F] fluoro-2-deoxy-d-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: Consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 3, 2011, Pages 747-755

  Inokuchi, Haruo ^a   Kodaira, Takeshi ^a   Tachibana, Hiroyuki ^a   Nakamura, Tatsuya ^b   Tomita, Natsuo ^a   Nakahara, Rie ^a   Takada, Akinori ^b   Mizoguchi, Nobutaka ^a   Tamaki, Tsuneo ^c   Fuwa, Nobukazu ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Southern TOHOKU Proton Therapy Center   (Japan)

^c Department of Radiology   (Japan)

Author keywords

Chemoradiotherapy; FDG PET; Fluoro 2 deoxy d glucose; Head and neck cancer; Planned neck dissection; Positron emission tomography; Prognosis

Indexed keywords

CHEMORADIOTHERAPY; FDG-PET; FLUORO 2 DEOXY D GLUCOSE; HEAD-AND-NECK CANCER; PLANNED NECK DISSECTION; PROGNOSIS;

DISEASE CONTROL; DISEASES; ELECTRONS; GLUCOSE; MULTIVARIANT ANALYSIS; PATHOLOGY; PATIENT MONITORING; POSITRONS;

POSITRON EMISSION TOMOGRAPHY;

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NEDAPLATIN; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NECK DISSECTION; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; CONFIDENCE INTERVAL; HEAD AND NECK TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECK DISSECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 79551473574     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.11.034     Document Type: Article

References (22)

1. J.P. Pignon, J. Bourhis, C. Domenge MACH-NC (Meta-Analysis of Chemotherapy on Head and Neck Cancer) Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data Lancet 355 2000 949 955
2. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
3. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
4. M.R. Posner, D.M. Hershock, and C.R. Blajman Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 2007 1705 1715
5. M. Yao, M.M. Graham, and H.T. Hoffman The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 59 2004 1001 1010
6. S.A. McHam, D.J. Adelstein, and L.A. Rybicki Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck 25 2003 791 798
7. E.A. Kidd, B.A. Siegel, and F. Dehdashti The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival Cancer 110 2007 1738 1744
8. R. Sasaki, R. Komaki, and H. Macapinlac [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer J Clin Oncol 23 2005 1136 1143
9. N. Fuwa, M. Kano, and T. Toita Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: A preliminary report of phase II study Radiother Oncol 61 2001 257 260
10. N. Fuwa, T. Kodaira, and K. Furutani Arterial chemoradiotherapy for locally advanced tongue cancer: Analysis of retrospective study of therapeutic results in 88 patients Int J Radiat Oncol Biol Phys 72 2008 1090 1100
11. N. Fuwa, T. Kodaira, and K. Furutani Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study Oral Oncol 43 2007 1014 1020
12. A.S. Allal, D.O. Slosman, and T. Kebdani Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose Int J Radiat Oncol Biol Phys 59 2004 1295 1300
13. H. Vesselle, R.A. Schmidt, and J.M. Pugsley Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 6 2000 3837 3844
14. S.M. Bentzen, B.M. Atasoy, and F.M. Daley Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial J Clin Oncol 23 2005 5560 5567
15. S.Y. Kim, J.L. Roh, and M.R. Kim Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx J Nucl Med 48 2007 752 757
16. J.L. Roh, K.H. Pae, and S.H. Choi 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx Eur J Surg Oncol 33 2007 790 795
17. H. Suzuki, Y. Hasegawa, and A. Terada FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma Oral Oncol 45 2009 569 573
18. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas Clin Adv Hematol Oncol 5 2007 79 81
19. S.C. Chan, J.T. Chang, and H.M. Wang Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value Oral Oncol 45 2009 52 58
20. S.W. Lee, S.Y. Nam, and K.C. Im Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography for nasopharyngeal carcinomas Radiother Oncol 87 2008 211 216
21. D.L. Schwartz, J. Rajendran, and B. Yueh FDG-PET prediction of head and neck squamous cell cancer outcomes Arch Otolaryngol Head Neck Surg 130 2004 1361 1367
22. C.T. Liao, J.T. Chang, and H.M. Wang Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes Int J Radiat Oncol Biol Phys 73 2009 764 771